Vanguard Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.8M Buy
2,303,381
+5,707
+0.2% +$63.2K ﹤0.01% 2352
2026
Q2
$55.3M Buy
2,297,674
+269,942
+13% +$8.18M ﹤0.01% 1887
2026
Q1
$61.6M Buy
+2,027,732
New +$54M ﹤0.01% 1744

Other funds holding CAPR

Vanguard Capital Management's CAPR Position: Q3 2026 in Review

Vanguard Capital Management increased its Capricor Therapeutics (CAPR) stake by 0.25% in Q3 2026, buying an estimated $63.2K and bringing the position to 2,303,381 shares worth $21.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2352.

Vanguard Capital Management first reported a position in CAPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $61.6M in Q1 2026. 157 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Vanguard Capital Management held 2,303,381 shares of Capricor Therapeutics worth $21.8M as of Q3 2026.
  • Vanguard Capital Management bought 5,707 Capricor Therapeutics shares in Q3 2026, an estimated $63.2K.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2352 holding.
  • Vanguard Capital Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Capricor Therapeutics position peaked at $61.6M in Q1 2026.
  • 157 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.